Investor news
Invitation to presentation of the Q3 report 2025
October 29, 2025
Oncopeptides AB will publish the report for the third quarter 2025, at 08:00 CET on November 5, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on November 5 at 09:00 CET.
Read more
Oncopeptides to host Capital Markets Update November 13
October 23, 2025
Oncopeptides will host a Capital Markets Update on November 13, 2025, from 09:00 to 12:00 CET, broadcast live from Inderes studio in Stockholm.
Read more
CEO Sofia Heigis presented at Aktiespararna
September 16, 2025
Oncopeptides CEO Sofia Heigis recently presented the company at the Aktiespararna event Aktiedagarna in Stockholm, September 16, 2025.
Read more
CEO Sofia Heigis interviewed by Redeye
August 25, 2025
Redeye’s analyst Richard Ramanius interviews Sofia regarding the Q2 report 2025.
Read more
Investor Q&A: Oncopeptides Rights Issue and Japan Partnership
August 21, 2025
Read more about why Oncopeptides is carrying out a new share issue, how the funds raised, and what you as a current or potential shareholder should think about.
Read more
Invitation to presentation of the Q2 report 2025
August 14, 2025
Oncopeptides will publish the report for the second quarter 2025, at 08:00 CET on August 21, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on August 21 at 09:00 CET.
Read more
Oncopeptides Partners with SD Pharma to further broaden Pepaxti reach in Spain
July 30, 2025
Oncopeptides AB today announces a partnership with SD Pharma, a leading Spanish pharmaceutical broker specializing in oncology and hematology. This strategic partnership will broaden physician reach of Pepaxti across hospital channels throughout Spain.
Read more
Sofia Heigis interviewed by Redeye
July 14, 2025
Redeye's analyst Richard Ramanius interviews Sofia regarding last week's newsflow. The interview is held in Swedish.
Read more
Oncopeptides announces net sales for Q2 2025
July 9, 2025
Oncopeptides releases this information ahead of the interim report for the second quarter 2025 as net sales are determined by the company to be higher than both the company´s projections and assumed market expectations.
Read more
Pepaxti included in European Guidelines for the treatment of multiple myeloma
July 8, 2025
Read more
Oncopeptides presented at the Aktiespararna event Aktiedagarna
June 10, 2025
Oncopeptides CFO Henrik Bergentoft recently presented the company at the Aktiedagarna event in Stockholm, June 10.
Read more
Sofia Heigis interviewed by Redeye
May 16, 2025
Oncopeptides CEO Sofia Heigis was recently interviewed by Richard Ramanius, equity analyst at Redeye, on the topic of the 2025 Q1 report.
Read more
Invitation to presentation of the Q1 report 2025
May 13, 2025
Oncopeptides AB will publish the report for the first quarter 2025, at 08:00 CET on May 15, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on May 15 at 09:00 CET.
Read more
Oncopeptides presented at the Redeye event Commercialization in Life Science
March 21, 2025
CEO Sofia Heigis recently presented the company at the Redeye event followed by a Q&A.
Read more
Oncopeptides presented at Stora Aktiedagarna Stockholm
March 12, 2025
Oncopeptides’ CEO Sofia Heigis recently presented the company at the Aktiespararna event Stora Aktiedagarna in Stockholm, Sweden. The presentation was followed by a Q&A with the moderator from Aktiespararna.
Read more
Invitation to presentation of the year-end report 2024
February 20, 2025
Oncopeptides AB will publish the report for the fourth quarter and the 2024 year-end report, at 08:00 CET on February 27, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on February 27 at 09:00 CET.
Read more
Oncopeptides presented at Aktiespararna Life Science 2025
January 30, 2025
Oncopeptides' CEO Sofia Heigis recently presented the company at the Aktiespararna event themed Life Science. The presentation is followed by a Q&A with moderator Lars Frick from Aktiespararna.
Read more
Sofia Heigis presented at Redeye Fight Cancer on January 22, 2025
January 22, 2025
Sofia Heigis, CEO of Oncopeptides, presented Oncopeptides at the Redeye Fight Cancer event on January 22. Apart from individual company presentations the event includes Q&A-sessions with each company as well as panel discussions.
Read more
Oncopeptides participated at Redeye Life Science event
December 4, 2024
Oncopeptides CEO Sofia Heigis recently participated at Redeye´s Technology and Life Science event in Stockholm.
Read more
Sofia Heigis presented at Stora Aktiedagarna
November 28, 2024
Oncopeptides' CEO Sofia Heigis presented the company at Stora Aktiedagarna organized by the organization Aktiespararna.
Read more
Sofia Heigis presented at BioStock Life Science Summit
November 22, 2024
You can watch the presentation and the following Q&A.
Read more
Oncopeptalks addressing your Q3 questions
November 12, 2024
In this episode of Oncopeptalks, David and Sofia discusses some of the questions received since the release of Oncopeptides’ Q3 report.
Read more
Sofia Heigis interviewed by Redeye
November 12, 2024
Oncopeptides CEO Sofia Heigis was recently interviewed by Richard Ramanius, equity analyst at Redeye on the topic of the recent Q3 report.
Read more
Invitation to presentation of the Q3 report 2024
October 31, 2024
Oncopeptides AB will publish the report for the third quarter of 2024, at 08:00 CET on November 7, 2024. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session, at 10:00 CET on the same day.
Read more
Oncopeptalks on South Korea, growth and pipeline
September 12, 2024
David and Sofia discusses the recent announcement on South Korea as well as some questions following the recent Q2 report presentation.
Read more
Oncopeptides presented at Aktiespararna event - theme Life Science
August 29, 2024
Oncopeptides Director of IR and Communications David Augustsson recently presented the company at the Aktiespararna event themed Life Science.
Read more
Invitation to presentation of the Q2 report 2024
August 8, 2024
Oncopeptides AB will publish the report for the second quarter of 2024, at 08:00 CET on August 14, 2024. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session, at 09:00 CET the same day.
Read more
Oncopeptalks on congresses and CD selection
June 27, 2024
Sofia and Oncopeptides’ congress chief discusses the importance of attending industry events, and Sofia gives her perspective on the recent SPiKE news.
Read more
Oncopeptides presented at Aktiespararna event
June 12, 2024
Oncopeptides CFO Henrik Bergentoft recently presented the company at the Aktiedagen event in Stockholm. See the presentation (in Swedish only)
Read more
CEO presentation from recent Annual General Meeting
June 5, 2024
Watch the presentation from CEO Sofia Heigis at the recent Annual General Meeting (AGM) held on May 31 in Stockholm.
Read more
Sofia Heigis interviewed at Redeye Growth Day
May 31, 2024
Sofia Heigis, CEO of Oncopeptides, was recently interviewed by equity analyst Richard Ramanius at Redeye´s event Growth Day 2024.
Read more
Oncopeptalks on Spain visit and rights issue
May 22, 2024
Sofia Heigis is back in the Oncopeptalks studio to talk about her visit to Spain to raise awareness of the company's launch there.
Read more
Invitation to presentation of the Q1 report 2024
May 21, 2024
Oncopeptides AB will publish the report for the first quarter of 2024, at 08:00 CET on May 30, 2024. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session, at 09:00 CET on the same day.
Read more
Oncopeptides participates in the MarketMakers podcast
April 25, 2024
Oncopeptides' CEO Sofia Heigis recently participated in MarketMakers, one of Sweden's largest financial podcasts.
Read more
Oncopeptalks featuring Cristina Bando, Spanish country manager
April 25, 2024
In this episode we meet with Cristina Bando, Spanish Country Manager at Oncopeptides for a short conversation on herself, the process of gaining market access in Spain and future of Pepaxti in Spain.
Read more
Sofia Heigis participated at Invest in Oncology Forum
April 11, 2024
Sofia Heigis recently presented Oncopeptides at the Invest in Oncology Forum, organized by Cord Communications. The presentation was followed by a Q&A session.
Read more
Oncopeptides held investor presentation at ProHearings
April 10, 2024
Oncopeptides' CEO Sofia Heigis recently presented the company to ProHearings, an independent channel for information to investors. Watch the presentation.
Read more
Biostock investor pitch: Oncopeptides
March 22, 2024
Sofia Heigis, CEO, presents Oncopeptides to BioStock, Scandinavia’s leading digital news and analysis service with an exclusive focus on companies in the Life Science sector.
Read more
Sofia Heigis interviewed by Redeye's life science analyst
March 19, 2024
On Monday, Oncopeptides' CEO Sofia Heigis was interviewed by Redeye's life science analyst Richard Ramanius. The conversation touched on, among other things, the recently announced new rights issue, what the European market for multiple myeloma drugs looks like and status on the ongoing commercialization in Europe.
Read more
Sofia Heigis presents at Redeye Commercialization in Life Science event on March 20
March 18, 2024
Oncopeptides’ CEO Sofia Heigis will present at Redeye’s event: Commercialization in Life Science on March 20, 2024.
Read more
Oncopeptides carries out rights issue
March 13, 2024
Listen to why Oncopeptides is carrying out a new share issue, where the money will go, what a rights issue really is and what you as a current or potential shareholder should think about.
Read more
Sofia Heigis presented at Stora Aktiedagarna in Stockholm
March 6, 2024
Sofia Heigis presented Oncopeptides on Tuesday at Stora Aktiedagarna in Stockholm. During her presentation, followed by a question and answer session, Sofia gave an update on the company, focusing on the changing treatment landscape for melflufen and commercialization in Europe. See the recorded presentation (in Swedish).
Read more
Oncopeptides to present at two investor events
March 4, 2024
March 4, 2024 - Oncopeptides CEO Sofia Heigis will be presenting at Aktiespararna’s event Stora Aktiedagen in Stockholm on March 5 and at Carnegie Healthcare Seminar 2024 on March 6.
Read more
Oncopeptalks on the recent FDA decision
February 27, 2024
February 27, 2024 – Jakob Lindberg, Chief Scientific Office about the FDA decision.
Read more
Invitation to presentation of the year-end report 2023
February 21, 2024
February 27, 2024 – Oncopeptides AB presents the report for the fourth quarter and the 2023 year-end report in a webcast and a subsequent Q&A session.
Read more
Oncopeptalks on the treatment landscape and competition
January 29, 2024
January 29, 2024 - Sofia Heigis deep dives into the rapidly changing treatment landscape.
Read more
Oncopeptides’ investor presentation and panel at Redeye published
January 26, 2024
January 26, 2024 - Earlier this week, Oncopeptides CEO Sofia Heigis presented at the Fight Cancer event hosted by investment bank Redeye. The company presentation was followed by a panel discussion together with Xpray Pharma CEO Per Andersson on the topic of commercialization and market access. Watch the presentation.
Read more
Sofia Heigis to present at Redeye Fight Cancer on January 24
January 22, 2024
January 24, 2024 - Sofia Heigis, CEO of Oncopeptides, will present Oncopeptides at the Redeye Fight Cancer event on January 24. Apart from individual company presentations the event includes Q and A-sessions with each company as well as panel discussions.
Read more
Henrik Bergentoft to present at Aktiespararna Södertälje on January 22
January 22, 2024
January 22, 2024 - Henrik Bergentoft, CFO of Oncopeptides, will present Oncopeptides at an Aktiespararna Södertälje investor event on January 22. The event is by invitation only.
Read more
End of year Oncopeptalks published
December 20, 2023
December 20, 2023 - CEO Sofia Heigis and IR Director David Augustsson cover the appeal in the U.S., sales in Europe in 2024 and beyond as well as share some highlights from this year’s ASH meeting.
Read more
The Q3 Earnings episode of Oncopeptalks
November 15, 2023
November 15, 2023 - David Augustsson, Director, Corporate Affairs, and CEO Sofia Heigis are leading this edition of Oncopeptalks.
Read more
The third episode of Oncopeptalks - Industry Congresses
October 20, 2023
October 20, 2023 - Join David Augustsson, Director of Corporate Affairs at Oncopeptides, for the third episode of Oncopeptalks together with CEO Sofia Heigis.
Read more
New information regarding Oncopeptides’ appeal of U.S. withdrawal published
September 21, 2023
Additional information regarding the formal request from the U.S. Food and Drug Administration (FDA) to voluntarily withdraw Pepaxto’s approval in the U.S has been made available in the public docket. More information and Q&A.
Read more
Oncopeptides launches "Oncopeptalks" with a fireside chat featuring CEO Sofia Heigis
September 20, 2023
Join David Augustsson, Director, Corporate Affairs at Oncopeptides, for the first edition of Oncopeptalks – a short company update aimed at investors where various members of the Oncopeptides team will be able to answer questions and address issues from the investor community.
Read more
CEO Sofia Heigis presented to Aktiespararna at Aktiedagen in Stockholm
September 19, 2023
On Tuesday, September 19, Sofia Heigis presented Oncopeptides at Aktiedagen in Stockholm, an event organized by Aktiespararna. The presentation can be viewed here and is available in Swedish only.
Read more
CHMP issues positive opinion on Type II variation to extend the therapeutic indication of Pepaxti based on OCEAN trial results
September 14, 2023
Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has, following their scientific assessment, adopted a positive opinion on Oncopeptides’ application for earlier lines of treatment for patients with relapsed, refractory multiple myeloma (RRMM). The opinion from the CHMP will now be sent to the European Commission for a final decision.
Read more
Stefan Norin named Chief Medical Officer at Oncopeptides
September 1, 2023
Oncopeptides today announces that Stefan Norin has been promoted to new Chief Medical Officer (CMO) at Oncopeptides, effective immediately.
Read more
Information regarding Oncopeptides’ appeal of U.S. withdrawal published
August 25, 2023
On August 25, 2023, more information regarding the formal request from the U.S. Food and Drug Administration (FDA) to voluntarily withdraw Pepaxto's approval in the U.S has been made available by the FDA.
Read more
Webcast - Presentation of the Q2 report 2023
August 6, 2023
Oncopeptides will publish the report for the second quarter 2023, at 08.00 (CET) on Thursday August 10, 2023, and will host a webcast on the same day at 09:00 (CET). Investors, financial analysts, and media are invited to participate in the webcast and following Q&A.
Read more
Oncopeptides complete first sales of Pepaxti in Greece
June 19, 2023
Oncopeptides today announced its first named patient sales of its flagship drug Pepaxti in Greece. The sales were made possible through Oncopeptides’ partnership with Ariti S.A., a company specialized on medical and pharmaceutical supply in Greece.
Read more
Presentation of the Q1 Interim report 2023
May 2, 2023
Oncopeptides AB (publ) published the report for the first quarter 2023, at 08.00 (CET) on Thursday May 4, 2023. Investors, financial analysts, and media were invited to participate in a webcast and a following QnA session at 09.00 (CET) on the same day.
Read more
Presentation of the year-end report 2022
February 9, 2023
Oncopeptides AB (publ) published the report for the fourth quarter and the 2022 year-end report, on February 16, 2023. Investors, financial analysts, and media were invited to participate in a webcast and a following QnA session on the same day. The event was hosted by Monica Shaw, CEO, together with Holger Lembrér, CFO, and Jakob Lindberg, CSO. The presentation was held in English.
Read more
DNB Healthcare Conference 2022 - presentation
December 15, 2022
On December 15, 2022, Oncopeptides CCO and Managing Director Germany, Sofia Heigis, gave a presentation at the DNB Healthcare Conference in Oslo, together with Dr. Fredrik Schjesvold from the Oslo Myeloma Center.
Read more
Fire side chat with CEO Jakob Lindberg at SEB's Annual Healthcare Seminar 2022
November 23, 2022
At SEB's Annual Healthcare Seminar 2022 Jakob Lindberg, CEO Oncopeptides, participated in a fire side chat with Dr. Christopher Uhde, Pharma/Biotec equity research at SEB.
Read more
Webcast - presentation of the Q3 report 2022
November 7, 2022
Oncopeptides published its report for the third quarter 2022 on November 9 at 08.00 (CET). On the same day at 14:00 (CET) investors, analysts, and media were invited to participate in a webcast and a following QnA session. The event was hosted by Chief Executive Officer Jakob Lindberg, together with Chief Commercial Officer Sofia Heigis and Chief Financial Officer Annika Muskantor. The presentations was held in English.
Read more
German launch - press conference
October 21, 2022
Friday October 21, 2022, Oncopeptides held a press conference to talk about the German launch of Pepaxti®.
Read more
Webcast - update from the ODAC meeting, Sep 22
September 23, 2022
September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population.
Read more
Webcast - presentation of the Q2 Interim Report 2022
August 9, 2022
Oncopeptides published its report for the second quarter 2022 on August 11, 2022, and hosted a webcast on the same day at 14:00 CET.
Read more
Webcast - CHMP rekommenderar att Oncopeptides Pepaxti får ett fullt godkännande i EU
June 23, 2022
June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.
Read more
CEO sitdown with Jakob - webcast June 1, 2022
June 1, 2022
CEO Jakob Lindberg took part in a webcast called CEO sitdown at Paues Åberg June 1, 2022. The interview is moderated by Caroline Wiken, partner at Paues Åberg.
Read more
ABGSC Life Science Summit 2022 - presentation
May 19, 2022
Oncopeptides CEO Jakob Lindberg presented at the ABGSC Life Science Summit 2022, May 19.
Read more
Webcast - Presentation of the Q1 Interim Report 2022
May 4, 2022
Oncopeptides published its report for the first quarter 2022 on May 4, 2022, and hosted a webcast on the same day.
Read more
Carnegie Healthcare Seminar 2022
March 17, 2022
Oncopeptides CEO Jakob Lindberg presented at Carnegie Healthcare Seminar 2022, March 17 at 16.45 CET. See the presentation below.
Read more
Webcast - Presentation of the Year-end Report 2021
February 17, 2022
Oncopeptides published its report for the fourth quarter and year-end results 2021 on February 17, 2022, and hosted a webcast on the same day.
Read more
Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto
January 21, 2022
Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US. Investors, financial analysts and media were invited to participate in a webcast with a Q&A session on January 24, 2022
Read more
Webcast - Presentation of the Q3 Interim Report 2021
November 24, 2021
Oncopeptides published its report for the third quarter 2021 on November 24, 2021, and hosted a webcast on the same day.
Read more
Jakob interviewed by Di.TV - as new CEO about going forward
November 15, 2021
In conjunction with the announcement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.
Read more
Webcast - Oncopeptides withdraw Pepaxto® in US, scale down organization and focus on R&D
October 22, 2021
October 22, 2021, Oncopeptides announced that the company has decided to withdraw Pepaxto® from the market in the US. The decision has been made after interactions and dialogue with the US Food and Drug Administration, FDA.
Read more
Handelsbanken Healthy Hour - presentation
September 15, 2021
Oncopeptides presented at Handelsbanken Healthy Hour on September 15. The presentation was held by CEO Marty J Duvall, CSO Klaas Bakker and CFO Anders Martin-Löf.
Read more
Webcast for presentation of OCEAN data presented at IMW
September 12, 2021
Oncopeptides presented data from the OCEAN study at the 18th International Myeloma Workshop (IMW) on September 11. Investors, financial analysts, and media were invited to participate in a webcast including a Q&A on September 12.
Read more
Presentation of the Q2 Interim Report 2021
August 19, 2021
Oncopeptides has published its report for the second quarter 2021 on August 19, 2021, and hosted a webcast on the same day at 12:00 CEST.
Read more
Presentation updated OCEAN data
July 8, 2021
Oncopeptides hosted a webcast on July 8, 2021, at 11:00 (CET) including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, and CMO Klaas Bakker.
Read more
Redeye Growth Day 2021 presentation
June 2, 2021
Oncopeptides' CFO Anders Martin-Löf presented at Redeye Growth Day 2021 , June 2.
Read more
Presentation of the Q1 Interim Report 2021
May 26, 2021
Oncopeptides has published the Q1 Interim Report 2021 and hosted a webcast the same day at 12:00 (CET), May 26, 2021.
Read more
Webcast - presentation of OCEAN topline data, May 25, 2021
May 25, 2021
In conjunction with the release of the topline data of the OCEAN study, Oncopeptides hosted a webcast May 25, 2021, at 11:00 (CET), including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas Bakker, and CFO Anders Martin-Löf.
Read more
Theme Day Commercialization of Medicine - Erik Penser Bank
May 6, 2021
Oncopeptides' CFO Anders Martin-Löf presented at Erik Penser Bank's theme day Commercialization of medical component on May 6 at 16:15 CET. The theme day was broadcasted live 09:00-17:00 CET.
Read more
Aktiedagen Stockholm - Aktiespararna
May 4, 2021
Oncopeptides' CFO Anders Martin-Löf presented at Aktiespararna's event Aktiedagen Stockholm on May 4 at 13:30 CET. The share day was broadcasted live from 07: 50-20:00 CET and 18 listed companies participated.
Read more
Cowen 41st Annual Health Care Conference - presentation
March 3, 2021
Oncopeptides' CEO Marty J Duvall presented at the Cowen 41st Annual Health Care Conference, March 3, 2021, at 17.00 CET.
Read more
Company Presentation March 2021
March 3, 2021
New Company Presentation for Oncopeptides, March 2021.
Read more
FDA approval of PEPAXTO - Webcast for investors, analysts and the media
March 1, 2021
In conjunction with the FDA approval of PEPAXTO February 26, Oncopeptides hosted a webcast March 1, 2021, at 07:30 (CET), including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas Bakker, and CFO Anders Martin-Löf.
Read more
Webcast Year-end Report 2020 presentation
February 18, 2021
Oncopeptides held a webcast February 18, 2021 at 14:00 (CET) when the Year-end Report 2020 and an operational update was presented by CEO Marty J Duvall, CMO Klaas Bakker and CFO Anders Martin-Löf.
Read more
Oncopeptides Virtual Capital Markets Day
November 30, 2020
“Building a Fully Integrated Biotechnology Company”
Read more
Jefferies London Health Care Conference presentation
November 18, 2020
Marty J Duvall presents at Jefferies London Health Care Conference, Wednesday December 18, 2020. The webcast was recorded. See presentation and link
Read more
DNB investor presentation
November 9, 2020
CEO Marty J Duvall presented at DNB Investor Call on November 9, 2020.
Read more
Citi’s 15th Annual BioPharma Virtual Conference – Presentation
September 10, 2020
Oncopeptides' CEO Marty J Duvall and CSO Jakob Lindberg presented at Citi’s 15th Annual BioPharma Virtual Conference. Please see attached presentation.
Read more
Pareto Securities 11:e Healthcare Conference – Presentation
September 2, 2020
Oncopeptides' CEO Marty J Duvall and CSO Jakob Lindberg presented at Pareto Securities Healthcare Conference.
Read more
Webcast regarding operational update Q2 2020
August 26, 2020
Oncopeptides held an operational update Wednesday August 26, 2020. It was presented by CEO Marty J Duvall, CSO Jakob Lindberg and CFO Anders Martin-Löf.
Read more
Nordea Small Cap Seminar – Presentation
August 12, 2020
Oncopeptides presented at Nordea Small Cap Seminar on Aug 12, 2020.
Read more
Jefferies Healthcare Conference June 3, 2020
June 3, 2020
Oncopeptides CEO presents at Jefferies Healthcare Conference at 1.30 – 1.55 PM (EDT) (19.30-19.55 CEST), June 3, 2020.
Read more
Webcast regarding operational update Q1 2020
May 26, 2020
Oncopeptides held an operational update Tuesday May 26, 2020. It was presented by CEO Jakob Lindberg and members of Oncopeptides management team.
Read more
Stockholm Corporate Finance Life Science Day – presentation
March 11, 2020
Oncopeptides’ CFO Anders Martin-Löf presented at the Stockholm Corporate Finance Life Science Day, March 11, 2020. See the recording of the presentation, and the presentation.
Read more
Webcast Year-End Report 2019
February 20, 2020
CEO Jakob Lindberg presented the Year-End report 2019 and an operational update at a webcast on February 20, 2020.
Read more
Presentation at SEB Annual Pharma & Biotech Seminar 2020
January 22, 2020
CEO Jakob Lindberg presented at SEB Annual Pharma & Biotech Seminar 2020, January 22, 2020.
Read more
2020 J.P. Morgan Health Care Conference – Presentation
January 15, 2020
Oncopeptides AB presented at the 38th Annual J.P. Morgan Healthcare Conference January 13 15, 2020 in San Francisco, US
Read more
Avanza Lunch Presentation
November 27, 2019
Oncopeptides’ CEO Jakob Lindberg presented at the Avanza Lunch meeting November 27, 2019. See the presentation as PDF
Read more
Investing in Oncology Forum 2019
October 7, 2019
Oncopeptides’ CFO Anders Martin-Löf held a presentation at Investing in Oncology Forum 2019 in Stockholm, Sweden, on October 7, 2019.
Read more
Pareto Health Care Conference 2019
September 5, 2019
Oncopeptides AB (publ) presented at the Pareto Securities Health Care Conference 2019. See attached presentation.
Read more
REDEYE Growth Day – Presentation
June 10, 2019
Oncopeptides CFO Anders Martin-Löf held a presentation at the REDEYE Growth Day, 10 June 2019. The Presentation was recorded and can be showed at the link below.
Read more
Jefferies 2019 Healthcare Conference, New York – Presentation
June 7, 2019
Oncopeptides CEO Jakob Lindberg gave a presentation at Jefferies Healthcare Conference in New York June 7, at 17.30 CET. The presentation was webcasted, see link below. You can also listen to the presentation, see the MP3 file below.
Read more
REDEYE Pre-ASCO Seminar – presentation
May 28, 2019
CEO Jakob Lindberg presented at the REDEYE Pre-ASCO Seminar, Tuesday May 28, in Stockholm, Sweden. See link to the recording of the presentation below.
Read more
Webcast regarding operational update
May 21, 2019
Oncopeptides held an operational update of the first quarter on Tuesday, May 21, 2019. It was presented by CEO Jakob Lindberg and members of the Oncopeptides management team.
Read more
Webcast regarding clinical program update
April 24, 2019
Oncopeptides held an webcast April 24, 2019, where CEO Jakob Lindberg provided new guidance on the patient recruitment in the OCEAN study and a clinical program update.
Read more
Kempen Life Science Conference 2019 – presentation
April 16, 2019
Oncopeptides' CFO Anders Martin-Löf presented at the Kempen Life Science Conference 2019 in Amsterdam, Netherlands, on April 16, 2019.
Read more
Cowen & Company 39th Annual Health Care Conference – Presentation
March 11, 2019
CEO Jakob Lindberg presented at Cowen and Company 39th Annual Health Care Conference on March 11, 2019. The presentation was webcasted.
Read more
Carnegie Healthcare Conference 2019 – presentation
March 6, 2019
Oncopeptides' CEO Jakob Lindberg presented at Carnegie Healthcare Conference, on March 6, 2019.
Read more
Webcast Year-End Report 2018
February 22, 2019
The Year-end Report for 2018 and an operational update was presented by CEO Jakob Lindberg and members of Oncopeptides management team, February 22, 2019.
Read more
SEB Biotech Seminar – presentation
January 24, 2019
Oncopeptides' CEO Jakob Lindberg presented at the SEB Biotech Seminar, January 24, 2019.
Read more
2019 J.P. Morgan Health Care Conference – Presentation
January 10, 2019
Paula Boultbee CCO and Anders Martin-Löf CFO presented at the 2019 J.P. Morgan Health Care Conference in San Francisco, US, January 7-10, 2019.
Read more
Oncopeptides Capital Markets Day in New York – presentations
December 14, 2018
Oncopeptides did host a Capital Markets Day on December 14th between 8.30-11.00 AM ET in New York, here is the presentation from the whole day.
Read more
DNB Nordic Healthcare Conference 2018 – presentation
December 12, 2018
December 12, CEO Jacob Lindberg held a presentation at the DNB Nordic Healthcare Conference 2018 in Oslo.
Read more
Jakob Lindberg, CEO, Oncopeptides – Company presentation post ASH
December 6, 2018
Jakob Lindberg, CEO, Oncopeptides held a Company presentation post ASH 2018.
Read more
Jefferies 2018 London Healthcare conference – Presentation & webcast
November 14, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies 2018 Healthcare conference in London November 14, 2018.
Read more
Lunch presentation at DNB
September 25, 2018
Corporate presentation by Jakob Lindberg, CEO, Oncopeptides AB (publ), at DNB 25 September 2018.
Read more
Jefferies Health Care conference, New York – Presentation
June 7, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies Healthcare Conference in New York June 7, 2018.
Read more
Jakob Lindberg, CEO, is interviewed in Di tv
May 17, 2018
Oncopeptides CEO Jakob Lindberg interviewed at DI Börsmorgon (Di tv) about the Q1 Interim report and the future, May 17, 2018.
Read more
Carnegie Healthcare Seminar 2018 – presentation
March 14, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Carnegie Healthcare Seminar on March 14, 2018.
Read more
SCF Life Science Seminarium – presentation
March 7, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Stockholm Corporate Finance Live Science Seminarium March 7 2018.
Read more
ABGSC Orphan Drug Day 2018 – Presentation
February 22, 2018
Oncopeptides presentation at ABGSC Orphan Drug Day at the ABG Office in Stockholm, Sweden, on February 22, 2018.
Read more
Jakob Lindberg interviewed in DI Börsmorgon
January 25, 2018
Oncopeptides CEO Jakob Lindberg is being interviewed in DI Börsmorgon, January 25, 2018.
Read more
JP Morgan, San Francisco – Presentation
January 10, 2018
Oncopeptides' CEO Jakob Lindberg presented at JP Morgan in San Francisco in January 8-10, 2018.
Read more
DNB Nordic Healthcare Conference 2017 – Oslo
December 14, 2017
Oncopeptides’ CEO Jakob Lindberg held a presentation at DNB Nordic Healthcare Conference in Oslo, December 14, 2017.
Read more
Carnegie Healthcare Day in New York – presentation
December 6, 2017
Oncopeptides' CEO Jakob Lindberg held a presentation at Carnegie Healthcare Day in New York on 5 December 2017.
Read more
Lunch at ABG – presentation
November 15, 2017
Jakob Lindberg, CEO of Oncopeptides, held a presentation at ABG on November 15, 2017.
Read more
Pareto Securities Healthcare conference 2017 – Presentation
September 7, 2017
Oncopeptides' CEO Jakob Lindberg presented at Pareto Securities Healthcare conference 2017.
Read more
Annual General Meeting 2017 – Presentation
May 18, 2017
The presentation held by CEO Jakob Lindberg at the Annual General Meeting 2017 at Tändstickspalatset, Stockholm, Sweden.
Read more
DNB SME Conference 2017
April 5, 2017
Oncopeptides' CEO Jakob Lindberg presented at DNB Small & Medium Enterprises Conference on April 5, 2017.
Read more
Carnegie Health Care Seminar
March 16, 2017
Oncopeptides' CEO Jakob Lindberg held a presentation at Carnegie Health Care Conference on March 16, 2017.
Read more
Redeye – Fight cancer-event
March 10, 2017
Jakob Lindberg, CEO of Oncopeptides AB, held a company presentation at the Redeye – Fight cancer-event on March 10, 2017.
Read more
Press release - October 29, 2025